Eyeworld

MAR 2016

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/649626

Contents of this Issue

Navigation

Page 141 of 178

THE POWER OF PREEMPTION OMIDRIA ® is the first and only FDA-approved drug that provides direct, continuous intracameral delivery of NSAID and mydriatic/anti-miotic therapy during cataract surgery 1 CHOOSE OMIDRIA FOR YOUR NEXT CATARACT SURGERY PATIENT • Preempt miosis—Maintain pupil dilation and optimize your operative field 1,2 • Block the surgically induced inflammatory cascade—Continuous delivery of OMIDRIA in the irrigation solution provides steady-state concentration of ketorolac and phenylephrine at the site of surgery 1 • Reduce postoperative pain—Patients are more likely to be pain free postoperatively, less likely to have moderate-to-severe pain, and less likely to use oral analgesics 1,3 • Eliminate the risks and liabilities of compounded products— OMIDRIA is FDA approved—it is GMP manufactured and the safety, efficacy, and drug product quality have been verified by the FDA 1,4 • Avoid coverage and reimbursement difficulties— Have confidence in reimbursement and provide your patients with the additional protection of OMIDRIAssure™ Visit OMIDRIAssure.com or call 1-877-OMIDRIA (1-877-664-3742) 9 am–6 pm ET, Monday–Friday Visit www.OMIDRIA.com ®

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld - MAR 2016